Summary Safety Review - Dipeptidylpeptidase-4 (DPP-4) Inhibitors - Assessing the Potential Risk of Heart Failure (English, HTML)

Summary Safety Review - Dipeptidylpeptidase-4 (DPP-4) Inhibitors - Assessing the Potential Risk of Heart Failure: English HTML file. From Health Canada, updated May 2024. View metadata, licence and the direct download on CanQuery.

Format
HTML
Access
Original download only
Publisher-reported update
2024-05-08

A safety review was carried out by Health Canada to evaluate the increased risk of heart failure with the use of DPP-4 inhibitors as a follow-up to a risk communication released by the U.S. FDA stating that saxagliptin and alogliptin might increase the risk of heart failure, in particular in patients who have other risk factors for heart failure. The product safety information in the U.S. and Canada were recently updated to include this risk.

Access original file

Data overview

Formats
HTML
File languages
English
Available actions
Access original file

Official sources and licences

Related open data